RxDoctor Payments Data

Kristen Wiese, PA

Physician Assistant · Reno, NVNPI 1578570354

Payments from drug & device makers

$1,605in general payments, 2019–2025

Across 22 payments — averaging $72.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$543
  • GSK$282
  • Bridgebio Pharma, Inc.$138
  • AstraZeneca$127
  • Esperion Therapeutics, Inc.$116
  • Corcept Therapeutics$114
  • plus $285 from 5 others

What the payments were for

  • Food & beverage$1,605100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,605 in reported general payments places this provider in the 70th percentile of 881 physician assistant providers in Nevada.

See all physician assistant providers in Nevada

Medicare billing

Part B allowed, 2024
$29,616
Medicare patients
127
Services billed
314

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide23$24,002
OzempicSemaglutide16$15,027
Atorvastatin Calcium73$1,205
Rosuvastatin Calcium64$1,119
Losartan Potassium43$638
Omeprazole39$631
Gabapentin32$572
Levothyroxine Sodium36$510
Lisinopril34$430
Albuterol Sulfate HfaAlbuterol Sulfate19$402
Tamsulosin Hcl25$377
Pravastatin Sodium12$363
Ezetimibe14$363
Bupropion XlBupropion Hcl18$334
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen24$319

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$32$24,00223 claims
Novo NordiskOzempic$543$15,02716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 881 physician assistant providers in Nevada.

Other physician assistant in Reno

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →